explore -WSS

explore

author：knowledge 2025-09-06 03:39:59 - browse：66276

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA advisers back CAR

WSS

FDA advisers vote against ALS treatment from BrainStorm

Ionis has late

Change Healthcare outage fallout shows need for new oversight

How the Dana

How the Dana

How one patient went off dialysis — and others can too

knowledge

explore

entertainment

At least 13 dead in Texas as scorching temps continue

Biogen shutters digital health group, ends Apple study, in cost cutting move

New air purifier tech could be key to improving indoor air quality

First U.S. drug developed to treat liver disease MASH is approved

Malaria cases in Florida and Texas: Here’s what you need to know

Why do women spend more than men on medical expenses?

As demand for Covid shots wanes, Moderna seeks its next success

Why do women spend more than men on medical expenses?

Hollywood unions extend contract negotiations for actors

Data show record exodus of life scientists from academia

focus

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Readout Newsletter: Bristol, Sangamo, Gilead, and more

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

How many hemophilia patients actually want gene therapy?

How many hemophilia patients actually want gene therapy?

FDA seeks to regulate lab

hotspot

hotspot

Wikipedia

explore